CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $122.63B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 4.55: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.10%Above 5Y avg (0.99%)
Annual Rate
USD 3.52Paid quarterly
Payout Ratio
39.8%Sustainable
Consecutive Growth
16 yrStrong track record
Paying Dividends
33 yr
Payback Period
94.6 yr
Last Ex-Dividend
Jun 30, 2026
Last Payment
Jul 31, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
122.63BUSDvs all stocks (USD)
Trailing P/E
38.31xRevenue (TTM)
25.27BUSDvs all stocks (USD)
Profit Margin
13.21%Beta
0.7780xvs all stocks
52-Week Change
-17.41%vs all stocks
Forward Annual Dividend Yield
1.10%vs all stocks
Market Capitalization
122.63BUSDvs all stocks (USD)
Enterprise Value
134.89BUSDvs all stocks (USD)
Trailing P/E
38.31xForward P/E
19.13xPEG Ratio
2.73xPrice to Sales (TTM)
4.85xPrice to Book (MRQ)
5.34xEnterprise to Revenue
5.34xEnterprise to EBITDA
19.50xGross Margin
63.29%Profit Margin
13.21%Operating Margin
17.82%Return on Assets (TTM)
7.72%Return on Equity (TTM)
15.20%Revenue (TTM)
25.27BUSDvs all stocks (USD)
Revenue per Share (TTM)
66.06USDUpdated Jul 19, 2026Quarterly Revenue Growth
2.60%Gross Profit (TTM)
16.35BUSDvs all stocks (USD)
EBITDA (TTM)
6.60BUSDvs all stocks (USD)
Net Income (TTM)
3.34BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.90%Operating Cash Flow (TTM)
5.38BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
4.36BUSDvs all stocks (USD)
Forward Annual Dividend Rate
3.52USDUpdated Jul 19, 2026Forward Annual Dividend Yield
1.10%vs all stocks
Trailing Annual Dividend Rate
3.48USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
1.09%vs all stocks
5-Year Average Dividend Yield
0.99%vs all stocks
Payout Ratio
39.81%Revenue
25.12BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
9.05BUSDFY2025 · Dec 31, 2025Gross Profit
16.07BUSDFY2025 · Dec 31, 2025Operating Income
5.06BUSDvs all stocks (USD)
Pre-tax Income
4.51BUSDFY2025 · Dec 31, 2025Income Tax Expense
1.27BUSDFY2025 · Dec 31, 2025Net Income
3.25BUSDFY2025 · Dec 31, 2025EBIT
5.12BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
6.48BUSDFY2025 · Dec 31, 2025Research & Development
1.62BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
8.65BUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
607.00MUSDFY2025 · Dec 31, 2025EPS (Basic)
8.49USDFY2025 · Dec 31, 2025EPS (Diluted)
8.40USDFY2025 · Dec 31, 2025Basic Shares Outstanding
382.20MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
382.20MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
3.25BUSDFY2025 · Dec 31, 2025Operating Cash Flow
4.70BUSDFY2025 · Dec 31, 2025Free Cash Flow
3.94BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.01BUSDFY2025 · Dec 31, 2025Income Tax Paid
1.00BUSDFY2025 · Dec 31, 2025Interest Paid
582.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
3.25BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.19BUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
392.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
243.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
173.00MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
127.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
94.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-767.00MUSDFY2025 · Dec 31, 2025Capital Expenditures
-761.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
-4.79BUSDFY2025 · Dec 31, 2025Other Investing Activity
-60.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.62BUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
2.98BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.40BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Common Dividends Paid
-1.28BUSDFY2025 · Dec 31, 2025Other Financing Charges
-182.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
113.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
383.36MSharesUpdated Jul 19, 2026Float Shares
347.57MSharesUpdated Jul 19, 2026Shares Short
6.92MSharesUpdated Jul 19, 2026Short Ratio
2.61daysvs all stocks
Short % of Shares Outstanding
1.88%vs all stocks
% Held by Insiders
5.37%vs all stocks
% Held by Institutions
82.57%vs all stocks
Total Cash (MRQ)
2.96BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.73USDUpdated Jul 19, 2026Total Debt (MRQ)
15.23BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6630xCurrent Ratio (MRQ)
2.11xBook Value per Share (MRQ)
59.94USDUpdated Jul 19, 2026Total Assets
47.84BUSDvs all stocks (USD)
Total Current Assets
14.76BUSDFY2025 · Dec 31, 2025Total Liabilities
25.42BUSDFY2025 · Dec 31, 2025Total Non-current Assets
33.09BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
17.63BUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.79BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.01BUSDFY2025 · Dec 31, 2025Other Short-term Investments
89.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
4.04BUSDFY2025 · Dec 31, 2025Inventory
5.31BUSDFY2025 · Dec 31, 2025Accounts Payable
1.80BUSDFY2025 · Dec 31, 2025Short-term Debt
1.00BUSDFY2025 · Dec 31, 2025Long-term Debt
14.86BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.37BUSDFY2025 · Dec 31, 2025Common Stock (Book)
38.00MUSDFY2025 · Dec 31, 2025Retained Earnings
20.47BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
22.42BUSDvs all stocks (USD)
52-Week Low
281.00USDUpdated Jul 19, 202652-Week High
404.87USDUpdated Jul 19, 202652-Week Change
-17.41%vs all stocks
Beta
0.7780xvs all stocks
50-Day MA
311.05USDUpdated Jul 19, 2026200-Day MA
345.07USDUpdated Jul 19, 2026Avg 10-Day Volume
2.54MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.62MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
8.35USDUpdated Jul 19, 2026Other Income / Expense
62.00MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Cash covers reported profit and gross profit is up, with margins high and growth slowing.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.55: safe zoneNotable
Altman Z-Score: 4.55
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $122.63B, higher than 95% of all stocks globallySignificant
Market cap (USD): 122,625,606,940Global P95: 25,614,208,870.135
Revenue is $25.27B, higher than 95% of all stocks globallySignificant
Revenue (USD): 25,269,999,616Global P95: 14,667,937,174.886
Levered free cash flow is $4.36B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 4,359,875,072Global P95: 1,123,592,359.78
Companies that share the same coordination system — how they create, deliver, or capture value.
Vertex Pharmaceuticals Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Bristol-Myers Squibb Company
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medtronic plc
Tier 1ProductionApproval-Gated PipelineRule
Pfizer Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GSK plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novo Nordisk A/S
Tier 1ProductionApproval-Gated PipelineRule
Gilead Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abbott Laboratories
Tier 1ProductionApproval-Gated PipelineRuleFlow
Amgen Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regeneron Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Happy Forgings Ltd
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Ecolab Inc.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Saab AB
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration